August 2026 Research Update

This month added more clarity about the early growth period in Prader-Willi syndrome and how growth hormone treatment relates to body composition over time. In one study, growth problems in early infancy became less common from 1 to 6 months, and children who started growth hormone while labeled as having failure to thrive showed larger early gains in lean tissue and reached similar lean mass levels after 5 years. A separate paper argued that starting growth hormone very early in life may have advantages for growth and development, but it was a synthesis of prior work rather than new trial results. [1] [2]

In the infant cohort, failure to thrive was reported in 29% at 1 month and 16% by 6 months, showing that early feeding and growth challenges are frequent but do not affect every baby. In the larger group of children treated with growth hormone for 5 years, 12% were classified as having failure to thrive when treatment started. Those children began with lower lean body mass but had greater catch-up in the first year and similar lean mass after 5 years. [1]

The review paper took a broader view and argued that starting recombinant growth hormone within the first year of life may improve growth, body composition, and some developmental outcomes, with acceptable safety when monitored. It also pointed out gaps, like limited long-term follow-up and mixed ways of measuring neurodevelopment, so the size of benefits at different starting ages is still not pinned down. This helps explain why timing of growth hormone is still being actively studied even though it is widely used in Prader-Willi syndrome. [2]

For families, these studies reinforce that early feeding and growth struggles can be a real part of Prader-Willi syndrome, especially in the first months, and that body composition (lean tissue and fat) is an important long-term focus in research. The new cohort data suggests that children who start growth hormone while underweight can still make substantial gains in lean tissue over time and may look similar to peers on lean mass after several years, but this is observational evidence rather than a head-to-head randomized comparison. The review supports the idea that earlier start could matter, yet it mainly gathers existing evidence and highlights unanswered questions, so it adds context more than it settles the timing question. [1] [2]

This month, studies describing day-to-day challenges in Prader-Willi syndrome highlighted two areas where patterns are becoming clearer: breathing during sleep and neurobehavioral diagnoses. One pediatric study found pulmonary hypertension was fairly common and was tied to hypoventilation, with no detectable link to having obstructive sleep apnea or to higher body mass index. Another larger cohort study reported autism and ADHD rates and found they did not differ by genetic subtype or growth hormone treatment, while anxiety showed some differences by subtype and by treatment status. [3] [4]

In the pulmonary hypertension study of 37 children, 27% met the study definition for pulmonary hypertension, and hypoventilation was the factor that separated those with pulmonary hypertension from those without it. The study did not detect a link between pulmonary hypertension and having obstructive sleep apnea, higher BMI, or growth hormone therapy in this small group. In plain terms, the results point to low breathing during sleep (not just snoring or apnea counts) as a potential signal of concern that researchers are trying to understand better. [3]

In a 292-person cohort followed over 3 years, autism spectrum disorder was reported in 19.5% and ADHD in 10.7%, and these rates did not significantly differ between deletion and maternal UPD genetic subtypes. The study also reported higher anxiety in the maternal UPD group than in deletion, and it found different anxiety and depression patterns between people who were and were not treated with growth hormone. Because this was observational, it cannot show that growth hormone caused any mental health differences, but it helps map which challenges are being seen in different subgroups. [4]

A separate study comparing sleep questionnaires across Angelman, Prader-Willi, and Rett syndromes found that night waking and snoring were elevated across all three conditions, including Prader-Willi syndrome. For Prader-Willi specifically, the study mainly adds a clearer picture of the kinds of sleep issues families report, but it did not include 12-month follow-up data for the Prader-Willi group. The authors noted that questionnaires were consistent measures, while also calling for more objective sleep testing in future research. [5]

These findings mainly add understanding of what health issues tend to cluster together in Prader-Willi syndrome, rather than changing care right away. The pulmonary hypertension study highlights that hypoventilation may be especially important to watch in research about heart-lung strain, but the study was small and from one center, so it needs confirmation. The behavioral cohort helps set expectations that autism and ADHD are reported in a notable minority of people with Prader-Willi syndrome and may not differ much by genetic subtype, while anxiety may differ by subtype; what drives those differences remains uncertain. The sleep questionnaire work gives families and researchers shared language for common sleep problems, but it does not replace objective sleep testing and did not track Prader-Willi changes over time in that dataset. [3] [4] [5]

Several papers this month focused on how Prader-Willi syndrome is identified and measured, and how care systems can support families. Across these studies, the main message is that diagnosis is not always straightforward (especially with unusual genetics or look-alike conditions), and that practical tools like telehealth testing and multidisciplinary clinic design are being evaluated to make assessments and care more accessible. Two case reports highlighted uncommon genetic situations that required detailed testing to untangle, while two method-focused papers addressed how to deliver assessments and clinic care more reliably. [6] [7] [8] [9]

One adult case report showed that blood-based methylation testing can miss mosaic maternal UPD(15)mat, where only a portion of cells carry the change. In that person, multi-tissue testing (including cheek cells) plus exome sequencing led to a dual diagnosis: Prader-Willi syndrome from mosaic UPD(15)mat and CADASIL from a NOTCH3 variant, supported by brain MRI findings. The report also described kidney disease in the same person, but it did not prove that CADASIL caused the kidney findings. [6]

A different case report looked at a well-known historical figure previously claimed to have Prader-Willi syndrome and found multiple inconsistencies with Prader-Willi, including unusually rapid early growth. Using historical growth information and AI-based facial phenotyping, the authors argued that MC4R deficiency (a genetic cause of severe early-onset obesity) fit better than Prader-Willi syndrome in that specific historical example. This work is not about diagnosing living patients from photos, but it highlights that severe early obesity has more than one possible cause. [7]

For measuring development and emotional play skills, one study found the Affect in Play Scale produced similar results whether done by telehealth video visit or in person for children ages 6 to 9, including those with Prader-Willi syndrome. Separately, a paper describing the EDUCATE framework reported that implementing a multidisciplinary Prader-Willi clinic improved access, care coordination, and family experience. Together, these studies add to the toolbox for delivering more consistent evaluations and coordinated visits, though they do not measure long-term health outcomes. [8] [9]

One additional case report, centered on Angelman syndrome, described unusual mosaic chromosome 15 inheritance and emphasized the value of high-resolution mapping to detect atypical imprinting transmission. While not a Prader-Willi study, it is relevant to the same chromosome 15 imprinting region and reinforces that rare genetic mechanisms can complicate standard testing approaches. [10]

For patients and caregivers, these studies mainly matter by explaining why genetic testing and careful interpretation can be complex in rare situations, especially when mosaicism is present or when another condition co-exists. The adult mosaic UPD case shows that a single blood test may not always tell the full story in unusual cases, and it illustrates how a second diagnosis can help make sense of additional symptoms, even though a single case cannot predict what will happen for others. The telehealth assessment and clinic framework papers suggest that access and coordination can potentially improve through new care delivery approaches, but they are about feasibility and service improvement rather than proving better long-term medical outcomes. The historical reanalysis showed that severe early obesity can have causes other than Prader-Willi syndrome, while the Angelman family report showed how an unusual inheritance pattern in the same chromosome 15 region can complicate genetic testing. [6] [8] [9] [7] [10]

Preclinical work this month focused on how brain circuits may be altered in Prader-Willi syndrome, using a mouse model. The study reported a specific mix of changes in brain cell structure and electrical behavior that could affect how signals are filtered and prioritized. This does not translate directly to symptoms in people, but it helps narrow down which cell types and pathways might be relevant to hyperphagia-related behaviors. [11]

In Snord116del mice, neurons in the anterior cingulate cortex showed signs of more complex branching and stronger excitatory connections than neurons from typical mice. At the same time, these cells had a more hyperpolarized resting state and reduced excitability at the cell body, along with improved signal discrimination and stronger low-pass filtering. The authors connected this pattern to previously observed better performance in working-for-food tasks and highlighted candidate genes and pathways, including mTOR signaling, as possible contributors. [11]

This is early laboratory research and is mainly about building a clearer biological picture rather than offering near-term changes for families. It suggests that, at least in one Prader-Willi mouse model, certain brain circuits may be wired to handle incoming signals differently, which could relate to how food cues are processed. What remains uncertain is how closely these mouse findings match the human brain and which of the highlighted pathways will turn out to matter for symptoms in people. For now, its value is in pointing researchers toward specific cell properties and pathways to study next. [11]